Related Experiment Videos
[Hemodynamic effects of oral captopril in patients with critical aortic stenosis]
C Martínez Sánchez1, O Henne, A Arceo
1Instituto Nacional de Cardiología Ignacio Chávez. (INCICH. Juan Badiano No.1, 14080, México, D.F.).
Insights
Captopril significantly improved hemodynamic function in patients with severe aortic stenosis, particularly those experiencing heart failure. This ACE inhibitor enhanced cardiac output and reduced vascular resistance.
Area of Science:
- Cardiology
- Pharmacology
- Hemodynamics
Context:
- Severe aortic stenosis presents significant hemodynamic challenges.
- Understanding the impact of pharmacologic interventions is crucial for patient management.
- Angiotensin-converting enzyme inhibitors (ACE inhibitors) are widely used cardiovascular drugs.
Purpose:
- To investigate the hemodynamic and ventricular function effects of oral captopril in patients with critical aortic stenosis.
- To assess the efficacy of captopril in improving cardiac performance in this patient group.
Summary:
- A prospective study analyzed 22 patients with critical aortic stenosis treated with captopril.
- Hemodynamic parameters significantly improved, including increased cardiac output and stroke volume, and decreased systemic vascular resistance.
- Patients with heart failure showed particular benefit, with reductions in pulmonary pressures.
Impact:
- Captopril demonstrates a beneficial effect on hemodynamic parameters in severe aortic stenosis.
- The findings suggest captopril may be a valuable therapeutic option, especially for patients with concomitant heart failure.
- This study contributes to the understanding of ACE inhibitor use in valvular heart disease.
Objectives:
To analyse the hemodynamic and ventricular function effects of oral captopril in severe aortic stenosis.
Patient Population:
inclusion criteria: patients older than 18 years with critical aortic stenosis.
Exclusion Criteria:
angiotensin-converting enzyme inhibitor used previously contraindication to right catheterisation aortic insufficiency, valvular prosthesis in aortic position, or other valvulopathy. As well as the need for immediate valvular aortic replacement arrhythmia, A-V conduction alterations, or ventilatory support.
Protocol:
prospective, no randomized. Swan-Ganz catheter was used. Basal hemodynamic measurements were made on 1, 2, 4, 6 and 8 hours during 48 hours. Captopril was administered 12.5 mg first and then 8 mg tid (6 doses).
Statistical Analysis:
Neuman-Keuls test was used for multivariate comparisons. Statistical significance was determined with P < 0.05.
Results:
22 patients were analyzed. Systemic vascular resistance fell from 1750 Dyn/seg/cm-5 to 1200 (P-0.001), cardiac output increased from 4.1l/min to 5.8 (P-0.001), cardiac index increased from 2.4 l/min/m2 to 2.9 (P-0.009), stroke volume from 47 ml to 64 (P-0.04) and stroke volume index from 27 ml/m2 to 36 (P-0.002). In patients with heart failure (n = 7) the systemic vascular resistance fell from 2050 Dyn/seg/cm-5 to 1463 (P-0.04), cardiac output increased from 2.8l/min to 4.1 (P-0.04), cardiac index from 2.07 l/min/m2 to 2.75 (P-0.04), stroke volume from 46 ml to 64 (P-0.03), pulmonary capillary wedge pressure fell from 19 mmHg to 16 (0.04) and the systolic pulmonary arterial pressure fell from 63 mmHg to 42 (P-0.009).
Conclusions:
captopril improves the hemodynamic parameters in patients with critical aortic stenosis, principally in those with heart failure.